
Nvidia begins a leadership transition after Huang’s immediate resignation.
Goldman Sachs says investors should prepare for a tougher stock-market backdrop as economic and earnings growth decelerate and market breadth narrows.
Goldman Sachs says the US stock market could face a more challenging year as economic growth and earnings growth remain positive but slow. The firm points to higher interest rates as a pressure on growth expectations, with the Atlanta Fed’s GDPNow estimate showing third-quarter GDP growth at 3.6%, down from an estimate above 6% earlier in the summer.
Goldman also forecast S&P 500 earnings growth slowing from around 29% in 2026 to 18% in 2027. For investors, the key takeaway is that a strong index level can mask a more fragile setup underneath.
Goldman’s strategists highlighted narrowing market breadth, meaning fewer stocks are driving gains compared with the number of laggards. Business Insider cited an October analysis from The Kobeissi Letter that found 84% of S&P 500 stocks were trading at least 10% below their all-time highs, even as the index sat near records.
The firm warned investors to be wary of Momentum factor exposure, especially after rapid gains in high-flying chip and memory stocks. The implication: leadership concentrated in a narrow group can leave portfolios more exposed if the trend reverses.
Goldman identified three areas to watch: consumer-facing laggards, health care stocks, and consumer staples stocks. Consumer-facing laggards could benefit if income growth accelerates for the lowest earners in 2027, while health care has typically performed well when growth is positive but decelerating.
Goldman said health care stocks have seen a median quarterly excess return of 1% over the S&P 500 in that type of environment. The bank also said consumer staples should outperform if the market continues to lower its growth outlook.
Goldman’s list focuses on health care and consumer staples names with low realized share-price volatility and high free-cash-flow yields relative to other stocks in their sectors. The 23 picks are: Tyson Foods (TSN, -5% YTD), Royalty Pharma (RPRX, +56%), CVS Health Corporation (CVS, +14%), JM Smucker Company (SJM, +31%), Kroger (KR, +0%), Cardinal Health (CAH, +23%), HCA Healthcare (HCA, -2%), Hormel Foods Corporation (HRL, -12%), Performance Food Group (PFGC, +8%), Sysco Corporation (SYY, +12%), Kenvue (KVUE, +8%), Hershey Company (HSY, -6%), US Foods Holding Corp (USFD, +34%), Merck & Co (MRK, +38%), ResMed (RMD, -2%), Quest Diagnostics Incorporated (DGX, +35%), Chemed Corporation (CHE, +19%), Abbott Laboratories (ABT, -15%), Mondelez International (MDLZ, +18%), McKesson Corporation (MCK, +21%), Church & Dwight Co (CHD, +26%), AbbVie (ABBV, +25%), and Colgate-Palmolive Company (CL, +20%).
The list is framed as a defensive screen for a slowing-growth market, not a broad call that all sectors will weaken. Investors can use it as a starting point to compare volatility, cash-flow strength, and sector exposure.

Nvidia begins a leadership transition after Huang’s immediate resignation.
The 2026 partner class is Goldman’s largest since 2010 and its biggest under CEO David Solomon.

Key takeaways from Fortune’s morning brief on Apple, markets, midterms and inflation.
Ackman says AI hyperscalers’ revenue growth could beat analyst expectations despite capex concerns.